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Cats were immunized three times with different recombinant feline immunodeficiency virus (FIV) candidate
vaccines. Recombinant vaccinia virus (rVV)-expressed envelope glycoprotein with (vGR657) or without
(vGR657x15) the cleavage site and an FIV envelope bacterial fusion protein (b-Galactosidase–Env) were
incorporated into immune-stimulating complexes or adjuvanted with Quil A. Although all immunized cats
developed antibodies against the envelope protein, only the cats vaccinated with the rVV-expressed envelope
glycoproteins developed antibodies which neutralized FIV infection of Crandell feline kidney cells. These
antibodies failed to neutralize infection of thymocytes with a molecularly cloned homologous FIV. After the
third immunization the cats were challenged with homologous FIV. Two weeks after challenge the cell-
associated viral load proved to be significantly higher in the cats immunized with vGR657 and vGR657x15 than
in the other cats. The cats immunized with vGR657 and vGR657x15 also developed antibodies against the Gag
proteins more rapidly than the cats immunized with b-Galactosidase–Env or the control cats. This suggested
that immunization with rVV-expressed glycoprotein of FIV results in enhanced infectivity of FIV. It was shown
that the observed enhancement could be transferred to naive cats with plasma collected at the day of challenge.
Feline immunodeficiency virus (FIV) is a T-lymphotropic
lentivirus that causes feline AIDS, which is similar to AIDS in
humans (1, 3, 9, 12, 20, 29, 39, 41, 45, 51). The similarities
between FIV and human immunodeficiency virus (HIV) on the
one hand and between the pathogeneses of the syndromes they
cause on the other hand have led to the use of FIV infection of
cats as an animal model to evaluate the potential of preventive
and therapeutic measures for HIV infection in humans. Since
FIV infection is widespread among cats all over the world, the
development of preventive and therapeutic measures for feline
AIDS is also of major veterinary importance.
Different vaccination strategies for lentivirus infections have
been evaluated with varying degrees of success. Most attempts
to develop candidate vaccines against lentivirus infections were
without success (for a review, see reference 22). Nevertheless,
in some experiments chimpanzees were successfully vaccinated
against HIV type 1 (HIV-1) (4) and macaques were success-
fully vaccinated against HIV-2 or simian immunodeficiency
virus (SIV) infections with candidate whole inactivated virus,
live attenuated virus, recombinant virus, subunit virus vaccines,
or combinations of these candidate vaccines (6, 7, 17, 21, 28,
30, 32, 38). The mechanisms by which protective immunity was
established in these systems are not well understood at present,
although there are indications for a major role of both virus-
neutralizing (VN) antibodies and cell-mediated immunity (10,
24, 31). However, contradictory data have also been obtained
in some of these studies (2, 5, 16, 18, 36). In the macaque SIV
model it was shown that at least part of the protective immu-
nity induced could be attributed not to virus-specific but rather
to cell-specific antibodies (23, 46). In the SIV system it was
recently shown that vaccine-induced protection against infec-
tion with SIV-infected cells correlated with the presence of a
certain major histocompatibility complex class I genotype of
the monkeys, indicating the involvement of major histocom-
patibility complex class I-restricted cytotoxic T-lymphocyte re-
sponses (11).
Several approaches to develop a preventive vaccine against
FIV infection have also proven to be unsuccessful (16, 48).
However, Yamamoto et al. reported the induction of protec-
tive immunity in cats against homologous and to a lesser extent
also to heterologous FIV challenge, by vaccination with inac-
tivated whole virus or FIV-infected cells (49, 50). This protec-
tive effect could be transferred to naive cats with plasma from
vaccinated animals, indicating that antibodies may be at the
basis of this protective immunity (13). It was shown that serum
antibodies against FIV envelope glycoproteins, with different
VN domains, correlated more with protective immunity than
did antibodies to other viral proteins.
FIV vaccines based on recombinant envelope proteins
would have clear advantages over inactivated or attenuated
virus vaccines. However, so far vaccination strategies using
FIV purified envelope glycoproteins or fractions of these pro-
teins as immunogens have failed (16, 26). Here we report the
results of a series of vaccination experiments in cats with dif-
ferent envelope proteins of FIV, expressed by recombinant
vaccinia viruses (rVV) or as a bacterial fusion protein and
presented in the context of different adjuvant systems. The
most striking finding of these studies is that vaccines containing
intact envelope glycoprotein induced enhancement of infectiv-
ity rather than protective immunity against homologous FIV
infection. The observed enhancement could be transferred to
naive cats with the plasma of the vaccinated cats.
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MATERIALS AND METHODS
Cells and challenge virus. Peripheral blood mononuclear cells (PBMC) and
thymocytes were derived from an 8-week-old specific-pathogen-free (SPF) cat
(42). These cells were stimulated with concanavalin A (5 mg/ml) in culture
medium (RPMI 1640 [GIBCO, Gaithersburg, Md.], penicillin [100 IU/ml], strep-
tomycin [100 mg/ml], L-glutamine [2 mM], 2-mercaptoethanol [2 3 1025 M],
interleukin-2 [100 IU/ml]) and 10% fetal calf serum. After 3 days the cells were
washed and cultured further in culture medium. An FIV-susceptible clone of
Crandell feline kidney (CrFK) cells, named CrFK 1D10, was kindly provided by
N. Pedersen (51). The FIV AM19 strain was isolated from PBMC of a cat
naturally infected with FIV (42). Concanavalin A- and interleukin-2-stimulated
cells were infected with FIV AM19. When FIV antigen was detected in culture
supernatant by enzyme-linked immunosorbent assay (ELISA) (40), it was filtered
through a 220-nm-pore-size filter, aliquoted, and stored at 21358C. This FIV
stock was titrated in vivo. Groups of four SPF cats were inoculated intramuscu-
larly with 0.5 ml of 1:100, 1:400, 1:1,600, 1:6,400, or 1:25,600 dilutions of the FIV
stock. All cats receiving 1:100 and 1:400 dilutions became infected by 4 to 8
weeks postinfection as shown by seroconversion and virus isolation. Three of the
four cats inoculated with 1:1,600-diluted FIV stock and one of the four cats
inoculated with 1:6,400-diluted stock became virus isolation positive and sero-
positive. One 50% cat infectious dose (CID50) was therefore estimated to be 0.5
ml of a 1:3,200 dilution of the FIV stock.
FIV AM6c was isolated from PBMC of a cat naturally infected with FIV and
adapted to replicate in CrFK 1D10 cells as previously described (43). env gene
sequence homology of FIV AM6c and FIV19k1 is 94.8%. CrFK 1D10 cells were
infected with FIV AM6c, and after 6 days the culture medium was refreshed.
After another 4 days of culture, when FIV antigen was detected in the culture
supernatant, it was filtered through a 220-nm-pore-size filter and stored in
aliquots at 21358C. This FIV stock was titrated in CrFK 1D10 cells and the
highest dilution (20 TCID50s) which consistently resulted in detectable antigen
production within 8 days was used in the VN assay (see below).
Preparation of candidate FIV vaccines. The envelope glycoproteins of FIV
AM19 were expressed by an rVV in BHK cells either in their native form
(vGR657) or after deletion of the cleavage site between the surface (SU) and the
transmembrane (TM) proteins (vGR657x15) to facilitate incorporation into im-
mune-stimulating complexes (iscoms) (33). After lectin purification these pro-
teins were incorporated into iscoms, which resulted in two iscom preparations—
vGR657 and vGR657x15 iscoms—as previously described (33). An 1,870-bp
fragment of the envelope gene was excised from pBluescript, containing the
whole envelope gene, by using the restriction enzymes BamHI and BglII (nucle-
otide positions 350 and 2220, respectively) and subcloned into BamHI-digested
pEX vector (Stratagene, La Jolla, Calif.). This vector allows inducible expression
of proteins as b-galactosidase (b-Gal) fusion protein. This protein was partially
purified as inclusion bodies, solubilized, and mixed with Quil A as an adjuvant.
SIV envelope glycoprotein iscoms were prepared by E. Hulskotte using a
method similar to that used for the cleavage site-deleted FIV envelope glyco-
protein iscoms (19).
Vaccination and challenge infection of cats. Six groups of six SPF cats each
were vaccinated three times subcutaneously according to the following schedule:
group 1, vGR657 iscoms; group 2, vGR657x15 iscoms; group 3, vGR657x15 plus
Quil A; group 4, b-Gal–FIV Env plus Quil A; group 5, SIV Env iscoms; and
group 6, phosphate-buffered saline. The cats were vaccinated with 10 mg of
protein at weeks 0, 4, and 10. Two weeks later the cats were challenged by the
intramuscular route with 20 CID50s of FIV AM19. PBMC and plasma samples
were collected every 2 weeks postchallenge (p.c.) during an 8-week period.
Serological assays. Antibodies against the Gag proteins p24 and p17 were
detected with a commercially available test kit, using recombinant p24 and p17
proteins (catalog number F1002-AB01; European Veterinary Laboratory B.V.,
Woerden, The Netherlands). Antibody titers were expressed as the optical den-
sity at 450 nm (OD450) value of the serum multiplied by the dilution divided by
three times the OD450 value of the negative control serum.
Antibodies against the envelope protein were detected by ELISA using syn-
thetic peptides and bacterial fusion proteins, representing different regions of the
envelope protein as shown in Fig. 1. The synthetic peptides were purchased from
European Veterinary Laboratory B.V. (catalog numbers: SU peptide, EVS-000-
PE-003; TM peptide, EVS-000-PE-004). The first synthetic peptide contains the
immunodominant VN epitope within variable region 3 spanning amino acid
residues 396 to 412 of the surface protein of the Petaluma strain (SU peptide)
(25). The second peptide contains a B-cell epitope between amino acid positions
695 and 706 of the transmembrane protein of the same FIV strain (TM peptide).
Antibody titers were calculated as described for the Gag ELISA.
An ELISA based on the detection of antibodies to a series of bacterial fusion
proteins as shown in Fig. 1 was performed as described elsewhere (8).
VN assays. VN serum antibodies were determined in two different VN assays.
The feline lymphocyte VN assay was based on inhibition of infection of thymo-
cytes with molecularly cloned FIV 19k1 as previously described (44). The CrFK
VN assay was based on the inhibition of infection of CrFK 1D10 cells with FIV
AM6c, which is adapted to replicate in these cells. For this assay CrFK 1D10 cells
(3.5 3 103) were seeded into a 96-well plate in 100 ml of Dulbecco modified
Eagle medium supplemented with 5% fetal calf serum. The next day the cells
were washed and incubated for 1 h at 378C with Polybrene (8 mg/ml) in Dulbecco
modified Eagle medium supplemented with 5% fetal calf serum. A mixture of
equal volumes of the diluted (see above) virus stock of FIV AM6c and twofold
serial dilutions of heat-inactivated serum was incubated for 1 h at 378C. Then the
CrFK cells were washed and incubated with the virus-serum mixture at 378C.
After 24 h the CrFK cells were washed twice and propagated in Dulbecco
modified Eagle medium supplemented with 2% fetal calf serum. After 8 days the
culture supernatant was tested for the presence of FIV antigen by ELISA (40).
The neutralizing antibody titer was expressed as the highest dilution of the serum
still preventing FIV antigen production in the culture supernatant.
Cell-associated virus load: infectious center test. Serially diluted PBMC sam-
ples (1 3 103, 3 3 103, and 1 3 104 cells) were prepared from cats before and
after challenge as previously described (42). These cells were cocultivated with
105 concanavalin A- and interleukin-2-stimulated PBMC from an SPF cat in
eight duplicate wells. After 3 weeks the culture supernatants were tested for the
presence of FIV antigen by ELISA. The number of infected cells in the PBMC
in vivo was calculated from the in vitro culture by assuming that one infected cell
gave rise to antigen production after cocultivation with concanavalin A- and
interleukin-2-stimulated PBMC from an SPF cat, when one or more cultures
tested in eight duplicate wells were negative for FIV antigen production.
Plasma transfer. A plasma pool was prepared by mixing equal volumes of the
plasma samples derived from all the vaccinated cats from groups 1 and 2 at the
day of challenge (plasma pool A). A second pool (plasma pool B) was prepared
similarly by mixing plasma samples from all the cats of group 6 at the day of
challenge. Two groups of four SPF cats, 10 weeks old, weighing between 800 and
1,250 g were used in the transfer experiment. Cats of group A and group B were
injected intravenously with 7 ml of plasma pool A and plasma pool B, respec-
tively. Six hours later the cats were challenged by the intramuscular route with 20
CID50s of FIV AM19 as described above. PBMC and plasma samples of the cats
were collected at weekly intervals and tested for viremia by virus isolation and for
the development of plasma antibodies against the Gag protein.
RESULTS
Development of FIV-specific plasma antibodies upon vacci-
nation. All plasma samples collected at the day of challenge
were tested in the SU and TM peptide ELISA (Table 1, week
p.c. 0). All the cats vaccinated with the vGR657 and
vGR657x15 iscoms (groups 1 and 2) had developed plasma
antibody titers to these peptides, ranging from 200 to 25,000,
whereas all the cats vaccinated with Quil A-adjuvanted
vGR657x15 (group 3) had developed antibody titers to at least
one of the two peptides ranging from 50 to 3,000. Five of six
cats vaccinated with the Quil A-adjuvanted bacterial FIV en-
velope fusion protein (group 4) had also developed serum
antibody titers to the TM peptide, ranging from 50 to 3,000,
whereas only one animal had developed a titer of 300 to the SU
peptide. One cat of the two control groups, groups 5 and 6,
showed an apparently nonspecific plasma antibody titer to the
SU and TM peptides, which already existed before the start of
the immunization procedure (not shown). Subsequently the
FIG. 1. Surface (SU1 to SU6) and transmembrane (TM1 to TM3) bacterial
fusion products and SU and TM peptides used in the ELISA to detect antibodies
against the envelope protein. The top bar represents the envelope protein of
FIV, including the leader (L), surface (SU), and transmembrane (TM) proteins.
The black boxes represent hypervariable regions in the envelope protein. The
different bacterial fusion products and the peptides are indicated as bars.
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same plasma samples were tested in ELISA for antibody titers
against the respective bacterial FIV envelope SU and TM
fusion proteins (Table 2). Vaccination with the vGR657- and
vGR657x15 iscoms (groups 1 and 2) resulted in high plasma
antibody responses to all the SU and TM regions tested with
the exception of the SU5 and TM1 regions, against which
lower or no antibody levels were detected. Antibody levels
induced with the native glycoprotein iscoms (group 1) and the
cleavage site-deleted envelope iscoms (group 2) are compara-
ble. The overall OD450 values induced with the cleavage site-
deleted FIV envelope glycoprotein adjuvanted with Quil A
(group 3) were lower than those found in the cats of groups 1
and 2. Vaccination with the b-Gal–FIV envelope fusion pro-
tein adjuvanted with Quil A failed to induce antibodies against
the SU1, SU2, SU4, and SU5 regions. No significant levels of
antibody to these fusion proteins were found in the cats of the
two control groups (groups 5 and 6).
All the plasma samples collected at the day of challenge
were also tested in the two VN antibody assays. None of the
samples exhibited VN activity in the feline lymphocyte VN
assay (not shown). However, VN antibodies could be demon-
strated in cats of groups 1, 2, and 3 in the CrFK VN assay (Fig.
2). The VN titers in cats vaccinated with vGR657 iscoms
(group 1) ranged from 160 to 640, with a mean titer of 506.
Those of vGR657x15 iscom-vaccinated cats (group 2) ranged
from 40 to 640 with a mean of 206, which is not significantly
different from the values found for group 1. VN plasma anti-
body titers of cats vaccinated with the Quil A-adjuvanted
vGR657x15 protein varied from 10 to 40, with a mean titer of
28, a value which is significantly lower than that found for
TABLE 1. Antibody response against SU and TM peptides in vaccinated cats at different times p.c.a
a SU peptide ELISA results: no symbol, titer , 200; n, titer between 200 and 1,000; n , titer between 1,000 and 5,000;
n , titer between 5,000 and 25,000;n , titer . 25,000. TM peptide ELISA results: no symbol, titer , 50; n, titer
between 50 and 300;n, titer between 300 and 3,000;n , titer between 3,000 and 10,000;n , titer . 10,000.
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groups 1 and 2 (Student t test; P , 0.05). In cats vaccinated
with the b-Gal–FIV envelope fusion protein (group 4) and the
cats of the control groups 5 and 6, no VN antibody response
could be demonstrated at the day of challenge.
As expected, none of the cats had developed plasma anti-
bodies to the FIV Gag protein at the day of challenge (Fig. 3).
Kinetics of FIV-specific plasma antibodies after FIV chal-
lenge. Plasma antibody titers against the SU and TM peptides
of most of the cats immunized with the recombinant FIV
envelope proteins (groups 1 to 4) increased 3- to 10-fold within
4 weeks after challenge infection. Within 8 weeks all the cats,
including the control animals in groups 5 and 6, had developed
anti-SU and anti-TM peptide plasma antibodies (Table 1). At
8 weeks p.c. the SU peptide-specific antibody titers in the cats
vaccinated with rVV-expressed FIV envelope glycoprotein
were significantly higher than those of the nonvaccinated cats
(Table 1; P , 0.05).
FIG. 2. Plasma VN antibody titers of the individual cats of the six different
vaccination groups as measured in the CrFK VN assay at the day of challenge.
The titers in the individual cats are indicated with different symbols. The mean
titer per group is indicated by a bar.
TABLE 2. Levels of antibody against envelope fragments in vaccinated cats at the day
of challengea
a No symbol, OD450 , 0.4; n, OD450 between 0.4 and 0.8;n, OD450 between 0.8 and 1.2;n, OD450 .
1.2.
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Plasma antibodies to the FIV Gag protein could be detected
4 weeks after challenge in all the cats vaccinated with rVV-
expressed FIV envelope glycoproteins (groups 1, 2, and 3)
(Fig. 3). In the cats vaccinated with the b-Gal–FIV envelope
fusion protein (group 4) and in the cats of the two control
groups, groups 5 and 6, it took about 2 weeks longer before
FIV Gag-specific antibodies were detected. Not only was the
induction of FIV Gag-specific antibodies in cats of groups 1 to
3 faster, but also the 8-week p.c. plasma titers tended to be
higher in these animals (Fig. 3).
Cell-associated virus load. Two weeks after infection FIV-
infected PBMC were demonstrated in all the cats of groups 1
and 2 and in four of six cats of group 3 (Fig. 4). The numbers
of FIV-infected PBMC varied from 50 to 210, 30 to 1,000, and
0 to 106 per 106 PBMC, respectively. In the other three groups
no infected PBMC were demonstrated at this time. Two weeks
later, FIV-infected PBMC could be demonstrated in all the
cats of all groups. Although a lower average FIV load was
observed in cats of group 4 compared with that in the other
groups, the differences observed between the groups proved
not to be significant.
Plasma transfer experiment. Pools of plasma collected at
the day of challenge from the cats of groups 1 and 2 (pool A)
and from group 6 (pool B) were prepared, and VN titers were
determined. The titers, measured in the CrFK VN assay, were
320 and ,10, respectively. Two groups of four SPF kittens
were inoculated intravenously with 7 ml of plasma pool A or
plasma pool B. No plasma VN antibodies could be detected 6
h after the transfer. FIV could be demonstrated in PBMC of
one of four cats of group A (20 infected cells per 106 PBMC)
but not in PBMC of cats of group B 2 weeks after challenge
with 20 CID50s of FIV AM19 (Fig. 5). Three weeks after
challenge three of four cats of group A and two of four cats of
group B exhibited cell-associated viremia, with significantly
higher numbers of FIV-infected cells in the cats of group A (P
, 0.05). The mean numbers of infected PBMC in the cats from
groups A and B at 3 weeks p.c. were 115 and 6 per 106 PBMC,
respectively (Fig. 5). At 4 weeks p.c. the mean numbers of
FIV-infected cells were 111 and 16 per 106 PBMC, respec-
tively. Five and six weeks after challenge FIV could be reiso-
lated from PBMC from all cats of both groups with no clear
differences in cell-associated virus load.
Four weeks after challenge, plasma antibodies to the Gag
FIG. 3. Kinetics of the plasma antibody titer development against the Gag
protein, in cats from the different vaccination groups. Mean anti-Gag titers at
different times after challenge are presented.
FIG. 4. Numbers of FIV-infected cells per 106 PBMC in the individual cats (indicated by different symbols) of the different vaccination groups at 2 and 4 weeks
p.c. The mean numbers of infected PBMC per group are indicated by a bar.
FIG. 5. Kinetics of numbers of FIV-infected cells per 106 PBMC in individual
cats (indicated by different bars) transferred with plasma pool A (groups 1 and
2) or plasma pool B (group 6), measured over 6 weeks p.c.
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protein could be detected in three of four cats of group A (with
ELISA titers ranging from 170 to 800) and in none of the cats
of group B (Fig. 6). At 5 weeks p.c. anti-FIV Gag plasma
antibodies were demonstrated in all cats of group A (titers
from 180 to 2,600) and in only two of four cats from group B
(titers from 70 to 100). In the plasma samples collected from
all the cats of both groups at 6 and 8 weeks p.c., antibodies
against the Gag protein were demonstrated. The titers were
significantly higher (P, 0.05) in the cats of group A than those
in the cats of group B from 4 weeks p.c. onward.
DISCUSSION
The present paper describes the evaluation of the potential
of different candidate FIV vaccines in a vaccination challenge
experiment in SPF cats. The most striking finding was that
immunization with rVV-expressed FIV glycoproteins, resulting
in VN plasma antibodies, led to enhanced FIV infection upon
challenge in these cats (groups 1, 2, and 3). This was demon-
strated by the more rapid development of PBMC-associated
viremia and Gag-specific plasma antibodies. The enhancement
effect could be transferred to naive cats with plasma collected
from cats immunized with these candidate vaccines. In con-
trast, cats immunized with an FIV envelope bacterial fusion
protein (group 4) did not develop VN plasma antibodies and
developed PBMC-associated viremia and Gag-specific plasma
antibodies with the same kinetics as the two control groups.
Comparison of the antibody levels induced in the first three
groups of cats at the day of challenge indicated that the im-
munogenicity of vGR657 and vGR657x15 incorporated into
iscoms was higher than that of vGR657x15 presented with Quil
A. Both VN plasma antibodies and plasma antibodies to the
different SU regions proved to be higher in the first two groups
(Fig. 2; Table 2). Plasma antibody levels against most of the SU
regions were lower or absent in group 4 at the day of challenge
(Table 2). It is not clear why the presence of VN plasma
antibodies at the day of challenge correlated not with protec-
tive immunity but rather with enhanced susceptibility to FIV
infection. It should be noted, however, that the VN activity was
demonstrable only in the CrFK VN assay and not in the feline
lymphocyte assay. The latter assay should probably be consid-
ered more relevant in terms of protective immunity against in
vivo FIV infection since, in contrast to feline kidney cells,
feline lymphocytes are natural targets for FIV infection. In the
transfer experiment it was shown that the enhancement phe-
nomenon could be transferred to naive cats with the plasma of
cats of groups 1 and 2. Although not formally proven, this
indicated that the enhancement was mediated by FIV enve-
lope-specific antibodies. The mechanism of enhancement
proved to be operational at relatively high dilutions: after
plasma transfer, no VN antibody activity could be demon-
strated in the plasma of the kittens which subsequently showed
enhanced FIV infectivity. It has also been shown for HIV-1
that antibody-dependent enhancement (ADE) could still be
demonstrated at high dilutions (up to 1:65,000), whereas VN
antibody activity can rarely be demonstrated at dilutions higher
than 1:1,000 (35). As no reliable systems are available at
present to quantify or even detect FIV-enhancing antibodies in
vitro, it should be realized that all FIV-neutralizing antibodies
found, per definition, should be considered to be the net result
of neutralization and enhancement of FIV infectivity mea-
sured in vitro.
To date different mechanisms of ADE have been described
for lentivirus infections. Complement- and Fc receptor-medi-
ated ADEs have been shown to play a role in HIV-1, HIV-2,
and SIV infections (14, 15, 27, 34, 47). Recently, another mech-
anism of ADE was described, in which antibodies neutralized
or enhanced HIV-1, dependent on the phenotype of the virus
involved (37). From our data it cannot be concluded which
mechanism was involved in the observed enhancement of FIV
infectivity. Indications for enhanced infectivity after FIV vac-
cination have been observed before (16). In the experiments of
Yamamoto et al. (50) the presence of VN antibodies, demon-
strated in an FeT1 cell (feline lymphoid cell line) VN assay,
correlated with protective immunity rather than with enhance-
ment of infectivity. This immunity could be transferred to naive
animals with plasma of immunized animals (13). The main
difference between their vaccination approach and ours is that
in our experiments recombinant envelope proteins were used
whereas Yamamoto et al. used inactivated whole virus or virus-
FIG. 6. Kinetics of plasma antibody titer development against the Gag protein in individual cats (indicated by different bars) transferred with plasma of pool A
(groups 1 and 2) or plasma of pool B (group 6).
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infected cells as immunogens. Since transfer experiments
showed that probably plasma antibodies are involved in the
observed mechanisms of enhancement and protection in both
series of experiments, it may be speculated that the differences
in configuration in which the FIV envelope glycoproteins were
presented in both vaccines led to VN antibodies with different
affinities. This may have had direct consequences for their in
vivo effects.
Furthermore, the cell substrates used for the production of
challenge viruses may have contributed to the observed differ-
ences in outcome of the vaccination experiments. The chal-
lenge virus used in our experiments was propagated in primary
feline lymphocytes, whereas the challenge viruses in the exper-
iments of Yamamoto et al. were propagated in a feline T-cell
line (50). Like in the HIV-1 system, T-cell line-adapted FIV
may be neutralized more efficiently than virus isolates from
primary lymphocyte cultures, which may result in neutraliza-
tion of the virus in the presence of enhancing antibodies. Fur-
thermore, it may be speculated that, as was recently demon-
strated for HIV-1 isolates from one individual (37), T-cell
line-adapted FIV is less susceptible to ADE.
Taken together, it should be stressed that the mechanisms
leading to the observed phenomenon of FIV enhancement
upon vaccination and passive transfer are not fully understood
at present. For the development of an effective FIV vaccine,
the elucidation of the underlying mechanisms may be crucial.
This may also lead to a more rational strategy for the devel-
opment of HIV-1 vaccines.
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